drugset / Trial / NCT02399449

IV Iron Safety: Evaluation of Iron Species in Healthy Subjects

NCT02399449

Phase 4 Completed 110 enrolled University of Maryland, Baltimore
RandomizedCrossoverOpen-labelBasic science

Summary

An approved treatment for anemia or low blood count due to chronic kidney disease is IV (intravenous, given into the vein) injection of an iron treatment. IV iron increases iron in the blood. Many IV iron therapies are now available in both brand name and generic forms. One common IV iron product is sodium ferric gluconate (SFG) sold as brand name Ferrlecit. Recently, a generic version of Ferrlecit was approved but was felt to be possibly more toxic than the brand product. The purpose of this research project is to see if the brand and generic IV iron products produce the same amount of iron in the blood in healthy volunteers, including an iron form that more toxic than other iron forms.

Timeline

Start
2017-09-15
Primary completion
2019-03-22
Completion
2019-04-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Sodium Ferric Gluconate Complex Unknown 125 mg Intravenous

Indications